ALK B ALK-ABELLO A/S

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  ALK-Abelló A/S held its Annual General Meeting on 16 March 2026.

The Annual General Meeting transacted the following business:

  • Approval of the annual report 2025 and discharge of the Board of Directors and Board of Management.
  • Resolution to declare that an ordinary dividend of DKK 1.6 per share of a nominal value of DKK 0.50, corresponding to a total dividend of DKK 355 million, was distributed to shareholders and that the remaining net profit of DKK 842 million was carried forward.
  • Adoption of the remuneration report for 2025.
  • Adoption of the remuneration to the Board of Directors for the present year.
  • Re-election of Anders Hedegaard as the Chair of the Board of Directors.
  • Re-election of Lene Skole as the Vice Chair of the Board of Directors.
  • Re-election of Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark and Alan Main to the Board of Directors.
  • PwC Statsautoriseret Revisionspartnerselskab was re-appointed as the company’s auditor in respect of statutory financial reporting as well as sustainability reporting.
  • Adoption of the following proposal from the Board of Directors:
    1. Approval of the updated remuneration policy.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at

Attachment



EN
16/03/2026

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til dir...

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige praksis har bestyrelsen truffet beslutning om at tildele indtil i alt 145.000 aktiebaserede instrumenter i overensstemmelse med selskabets langsigtede incitamentsprogram (LTIP) for direktion og en kreds af ledende medarbejdere for 2026. Formålet med LTIP er at tilskynde og belønne langsigtet vær...

12h / 42m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Grant of share-based long-term incentive instruments to members of the...

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 145,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2026. The objectives of the LTIP are to incentivise and reward lon...

12h / 42m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy 1 mg approved across the EU as the first and only needle-free...

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) granted marketing authorisation for EURneffy® 1 mg – extending a class of treatment previously available only by injection. EURneffy® 1 mg is now indicated for the emergency treatment of anaphylaxis due to insect stings or bites, foods, me...

March 31, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026

Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026 ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  ALK-Abelló A/S afholdt ordinær generalforsamling den 16. marts 2026. På generalforsamlingen skete følgende: Årsrapport 2025 blev godkendt, og der blev meddelt decharge for bestyrelse og direktion.Der blev truffet beslutning om at udbetale et ordinært udbytte på 1,6 kr. pr. aktie a en nominel værdi på 0,50 kr. til aktionærerne, svarende til et samlet udbytte på DKK 355 mio., og at det resterende nettooverskud på DKK 842 mio. blev overført til næste regnskabsår. Vederlagsrapporten for 2...

March 16, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026 ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual report 2025 and discharge of the Board of Directors and Board of Management.Resolution to declare that an ordinary dividend of DKK 1.6 per share of a nominal value of DKK 0.50, corresponding to a total dividend of DKK 355 million, was distributed to shareholders and that the remaining net profit of DKK 842 million was carried forward.Ado...

March 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch